Inflammatory Bowel Disease Drugs Market
Global Inflammatory bowel disease drugs Market Size, Share & Trends Analysis Report by Type (Crohn’s disease and Ulcerative colitis), By Drug (Aminosalicylates, Corticosteroids, TNF Inhibitors, IL Inhibitors, Anti-integrin, JAK Inhibitors, and Others) By Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) Forecast 2022-2028
The global Inflammatory bowel disease drugs market is anticipated to be at a considerable CAGR of 4.7%. Inflammatory bowel disease (IBD) causes inflammation or swelling in the intestines or broadly in the digestive tract. This inflammation prevails with chronic pain in the digestive tract. Poor appetite, diarrhoea, and poor digestion are signs of IBD. The rising prevalence of Crohn’s disease and ulcerative disease across the globe is expected to drive market growth over the forecast period. According to Crohn’s and colitis foundation of the US, every year around 70,000 cases of IBD are diagnosed in the US. Medicines and drugs are introduced for the effective treatment of IBD. Moreover, increasing adoption of biologics for the treatment and the presence of strong pipeline drugs such as upadacitinib, risankizumab, tofacitinib, ustekinumab, and others is anticipated to boost the market growth in the coming years. For instance, in May 2021, the Food and Drug Administration of the US has approved the Zeposia drug for the treatment of ulcerative colitis. This drug was approved after a trial of 10 weeks.
Impact of COVID-19 Pandemic on Global Inflammatory bowel disease drugs Market
Covid-19 pandemic has affected every sector of the world. The health sector saw a downfall during covid 19 as necessary treatment was not available to people during this time. Hospital facilities and drug stores were not in operation so this market experienced a downfall during this time. IBD medicines are taken as per prescription by health experts who were not available during this time.
Segmental Outlook
The global Inflammatory bowel disease drugs market is segmented based on type, drug, and distribution channel. Based on type, the market is segmented into Crohn’s disease and Ulcerative colitis. Based on the drug, the market is sub-segmented into Aminosalicylates, Corticosteroids, TNF Inhibitors, IL Inhibitors, Anti-integrin, JAK Inhibitors, and others. Based on the distribution channel the market is sub-segmented into hospital pharmacy, online pharmacy, and retail pharmacy. Among the above-mentioned segments, the hospital pharmacy segment is going to see considerable growth as people in these serious conditions go to some medical experts. Gastroenterologist operates on any issues is in the digestive tract. They prescribe drugs that are available in hospitals in which that gastro facility is as these are long-term prescription drugs.
Global Inflammatory bowel disease drugs Market Share by Type, 2021 (%)
Crohn’s Disease Segment is Anticipated to Hold a Prominent Share in the Global Inflammatory Bowel Disease Drugs Market
Crohn’s disease is anticipated to hold a prominent market share in the global Inflammatory bowel disease drugs market during the forecast period. Crohn’s disease can affect any part of the gastrointestinal tract starting from the mouth to the small intestine. It commonly affects the end part where the small intestine ends which is known as the ileum. This disease affects some parts of the GI tract while leaving other parts completely untouched. The entire thickness of the bowel wall can get inflamed if the GI tract is infected by Crohn’s disease. Genetic predisposition, immune system disturbance, and Environmental triggers are the primary cause of Crohn’s disease. For instance, in Feb 2021, Scientists from Ann & Robert H Lurie Children’s hospital in Chicago have demonstrated a nano therapy that will be helpful in reducing intestine inflammation in serious Crohn’s disease.
Regional Outlooks
The global Inflammatory bowel disease drugs market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). In Asia Pacific, the market for inflammatory bowel disease treatment is anticipated to grow at the fastest rate over the forecast period. The increasing prevalence of Crohn’s disease and ulcerative colitis in the region’s major economies and rising novel drug approval are expected to drive the regional market growth during the forecast period.
Global Inflammatory Bowel Disease Drugs Market Growth, by Region 2022-2028
North America is Estimated to Hold the Major Share in the Global Inflammatory bowel disease drugs Market
Geographically, it is anticipated that the major share of the market will be taken by North America and this region will lead during the forecast period. People with inflammatory bowel disease are increasing at a consistent rate in North America. As per Statista, there were around 2.5 million people with Inflammatory bowel disease in the US in the year 2020. It is estimated that this figure will rise to 3.5 million by the year 2030. A major reason for the prevalence of IBD in this region is decreasing immunity among people. When outside bacteria and fungi enter the human intestine, our immune system protects our gut. People with weak immunity are more likely to get affected. For instance, in Jan 2022, M.Ellen Kuenzig from the hospital of sick children in Toronto and his fellow mates conducted a review to examine the prevalence of IBD in children below 21. They found that the prevalence of IBD was highest in North America. This review was published in the journal Gastroenterology.
Market Players Outlook
The major companies serving the global Inflammatory bowel disease drugs market include AbbVie Inc., Biogen, Johnson & Johnson Services, Inc., Amgen Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Pfizer Inc, Mergers and acquisitions, new product launches, business expansion, partnership collaboration are done by market players in this field. For instance, in Nov 2021, an application has been submitted by Abbvie to the European medicine agency for the approval of Risankizumab which will be used for the treatment of Crohn’s disease in patients above 16 years.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Inflammatory bowel disease drugs market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on The Global Inflammatory bowel disease drugs Market
• Recovery Scenario of Global Inflammatory bowel disease drugs Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Abbvie Inc.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Biogen Inc.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Johnson and Johnson Services, Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Amgen Inc.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. UCB Biopharma SRL
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Inflammatory bowel disease drugs Market by Type
4.1.1. Crohn’s disease
4.1.2. Ulcerative colitis
4.2. Global Inflammatory bowel disease drugs Market by Drugs
4.2.1. Aminosalicylates
4.2.2. Corticosteroids
4.2.3. TNF Inhibitors
4.2.4. IL Inhibitors
4.2.5. Anti-integrin
4.2.6. JAK Inhibitors
4.3. Global Inflammatory bowel disease drugs Market by Distribution Channel
4.3.1. Hospital pharmacy
4.3.2. Online pharmacy
4.3.3. Retail pharmacy
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Abbott Laboratories
6.2. Alkem Laboratories Ltd.
6.3. Allergan PLC
6.4. Bausch Health Companies Inc.
6.5. Eli lilly and Company
6.6. Janssen Global services, LLC
6.7. Merck & Corp., Inc.
6.8. Novartis AG
6.9. Pfizer Inc.
6.10. Takeda Pharmaceutical company Ltd.
1. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL CROHN’S DISEASE INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL ULCERATIVE COLITIS INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG, 2021-2028 ($ MILLION)
5. GLOBAL AMINOSALICYLATES INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL CORTICOSTEROIDS INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL TNF INHIBITORS INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL IL INHIBITORS INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL ANTI INTEGRIN INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL JAK INHIBITORS INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
12. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS IN HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS IN ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS IN RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
15. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
16. NORTH AMERICAN INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. NORTH AMERICAN INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
18. NORTH AMERICAN INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG, 2021-2028 ($ MILLION)
19. NORTH AMERICAN INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
20. EUROPEAN INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. EUROPEAN INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
22. EUROPEAN INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG, 2021-2028 ($ MILLION)
23. EUROPEAN INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
24. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
25. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS TYPE, 2021-2028 ($ MILLION)
26. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG, 2021-2028 ($ MILLION)
27. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
28. REST OF THE WORLD INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
29. REST OF THE WORLD INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
30. REST OF THE WORLD INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG, 2021-2028 ($ MILLION)
31. REST OF THE WORLD INFLAMMATORY BOWEL DISEASE DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET, 2021-2027 (%)
4. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL CROHN’S DISEASE INFLAMMATORY BOWEL DISEASE DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL ULCERATIVE COLITIS INFLAMMATORY BOWEL DISEASE DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET SHARE BY DRUG, 2021 VS 2028 (%)
8. GLOBAL AMINOSALICYLATES INFLAMMATORY BOWEL DISEASE DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL CORTICOSTEROIDS INFLAMMATORY BOWEL DISEASE DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL TNF INHIBITORS INFLAMMATORY BOWEL DISEASE DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL IL INHIBITORS INFLAMMATORY BOWEL DISEASE DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL ANTI INTEGRIN INFLAMMATORY BOWEL DISEASE DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL JAK INHIBITORS INFLAMMATORY BOWEL DISEASE DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
15. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET IN HOSPITAL PHARMACY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET IN ONLINE PHARMACY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
17. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET IN RETAIL PHARMACY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
18. GLOBAL INFLAMMATORY BOWEL DISEASE DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
19. US INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
20. CANADA INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
21. UK INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
22. FRANCE INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
23. GERMANY INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
24. ITALY INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
25. SPAIN INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF EUROPE INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
27. INDIA INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
28. CHINA INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
29. JAPAN INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
30. SOUTH KOREA INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
31. REST OF ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
32. REST OF THE WORLD INFLAMMATORY BOWEL DISEASE DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
